Related Experiment Video
Updated: Jun 28, 2026
Radial Mobility and Cytotoxic Function of Retroviral Replicating Vector Transduced, Non-adherent Alloresponsive T Lymphocytes
Published on: February 11, 2015
RGD-IL-24, a novel tumor-targeted fusion cytokine: expression, purification and functional evaluation
1Department of Clinical Microbiology and Immunology, Faculty of Medical Laboratory Science, Third Military Medical University, Chongqing, 400038, People's Republic of China.
Abstract:
Targeting drugs to tumor cells is a central challenge for improving existing cancer therapies. ACDCRGDCFCG peptide (RGD-4C) binds to alphavbeta3 integrin, which is selectively expressed in tumor blood vessels and on the surface of some tumor cells. Interleukin 24 (IL-24) is a novel cancer growth-suppressing and apoptosis-inducing cytokine. To enhance the antitumor effect, we coupled RGD-4C to the N-terminus of IL-24 and expressed RGD-IL-24 in Escherichia coli. Cell proliferation and adhesion experiments revealed that RGD-IL-24 specifically binds to MCF-7 cancer cells, and induces apoptosis of MCF-7 cancer cells. These studies support the use of the RGD-IL-24 protein in tumor-targeting therapy.
Insights
This study developed RGD-IL-24, a targeted cancer therapy. This novel protein binds to tumor cells and induces apoptosis, showing promise for improved cancer treatment.
Area of Science:
- Biotechnology
- Molecular Biology
- Oncology
Background:
- Targeting therapies to tumor cells is crucial for enhancing cancer treatment efficacy.
- Integrins, such as alphavbeta3, are overexpressed in tumor vasculature and on cancer cells, presenting a therapeutic target.
- Interleukin 24 (IL-24) is a cytokine with demonstrated cancer growth-suppressing and apoptosis-inducing properties.
Purpose of the Study:
- To develop a novel tumor-targeting therapeutic agent by conjugating the RGD-4C peptide to Interleukin 24 (IL-24).
- To investigate the specific binding and anti-cancer effects of the engineered RGD-IL-24 protein on cancer cells.
- To evaluate the potential of RGD-IL-24 in targeted cancer therapy.
Main Methods:
- The RGD-4C peptide was chemically coupled to the N-terminus of IL-24.
- The recombinant RGD-IL-24 protein was expressed in Escherichia coli.
- Cell proliferation and adhesion assays were performed using MCF-7 cancer cells to assess RGD-IL-24's efficacy.
Main Results:
- RGD-IL-24 demonstrated specific binding to MCF-7 cancer cells.
- The engineered protein successfully induced apoptosis in MCF-7 cancer cells.
- These findings indicate targeted delivery and cytotoxic effects of RGD-IL-24.
Conclusions:
- The RGD-IL-24 fusion protein exhibits specific tumor-targeting capabilities.
- RGD-IL-24 effectively induces cancer cell apoptosis, supporting its potential as a therapeutic agent.
- This targeted approach holds promise for advancing cancer therapy strategies.
